Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
132.4 SAR | -0.90% | -1.05% | -3.36% |
May. 08 | Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises | MT |
Mar. 18 | Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.36% | 4.63B | D- | ||
-41.10% | 13.83B | B- | ||
-28.13% | 11.5B | B | ||
+14.31% | 6.41B | C | ||
-19.34% | 6.32B | B | ||
-13.46% | 5.97B | C+ | ||
+72.00% | 5B | C | ||
-6.07% | 3.96B | B | ||
-18.47% | 3.24B | C- | ||
-12.61% | 2.85B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4164 Stock
- Ratings Nahdi Medical Company